Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.

Eli Lilly (LLY 0.16%) and Novo Nordisk (NVO-1.00%) are locked in an intensifying conflict for control over the markets for weight loss and type 2 diabetes treatments.

Eli Lilly’s revenue has grown at an average annual rate of 17.4% over the past three years (vs. 6.2% for the S&P 500) Revenue rose 32.0% from $34 billion to $45 billion over the past year ...

Eli Lilly (LLY 0.68%) is one of the hottest pharmaceutical companies in the world. The company is quickly gaining steam in the weight loss market thanks to its blockbuster drug, ...

Eli Lilly has had a total return of 60% over the last 12 months, and its gains could get even better. This is only Mounjaro's first full year on the market, ...